Search results for "idiot"

showing 4 items of 44 documents

Erythropoietin and its lost receptor [8]

2007

TransplantationTumorReproducibility of ResultsImmunohistochemistrySensitivity and SpecificityAntibodiesCell LineRatsMiceerytropoietinKidney TubulesAnti-IdiotypicNephrologyReceptorsAnimalsHumansRabbitsAnimals; Cell Line Tumor; Erythropoietin; Humans; Immunohistochemistry; Kidney Tubules; Mice; Rabbits; Rats; Receptors Erythropoietin; Reproducibility of Results; Sensitivity and Specificity; Antibodies Anti-Idiotypic; Nephrology; TransplantationErythropoietin
researchProduct

Minkowski - L’idiot

2015

International audience

[ SHS.PHIL ] Humanities and Social Sciences/Philosophy[SHS.PHIL] Humanities and Social Sciences/Philosophy[ SHS.HIST ] Humanities and Social Sciences/History[SHS.HIST] Humanities and Social Sciences/History[SHS.PHIL]Humanities and Social Sciences/PhilosophyMinkowski[SHS.HIST]Humanities and Social Sciences/HistoryComputingMilieux_MISCELLANEOUSidiot
researchProduct

Yeast Killer Toxin-Like Candidacidal Ab6 Antibodies Elicited through the Manipulation of the Idiotypic Cascade

2014

A mouse anti-anti-anti-idiotypic (Id) IgM monoclonal antibody (mAb K20, Ab4), functionally mimicking a Wyckerhamomyces anomalus (Pichia anomala) killer toxin (KT) characterized by fungicidal activity against yeasts presenting specific cell wall receptors (KTR) mainly constituted by β-1,3-glucan, was produced from animals presenting anti-KT Abs (Ab3) following immunization with a rat IgM anti-Id KT-like mAb (mAb K10, Ab2). MAb K10 was produced by immunization with a KT-neutralizing mAb (mAb KT4, Ab1) bearing the internal image of KTR. MAb K20, likewise mAb K10, proved to be fungicidal in vitro against KT-sensitive Candida albicans cells, an activity neutralized by mAb KT4, and was capable of…

beta-GlucansPhage displayImmunogenPichia anomalaHumoral Immune ResponseAntibody Responselcsh:MedicinePichiaMiceCandida albicansVaccines DNAlcsh:ScienceImmune ResponseMultidisciplinaryVaccinationCandidiasisInfectious Disease ImmunologyKiller Factors YeastAntibodies Anti-IdiotypicVaccines SubunitResearch Articlemedicine.drug_classMolecular Sequence DataImmunologyReceptors Cell SurfaceMycologyBiologyMonoclonal antibodyMicrobiologyMicrobiologyFungal ProteinsAntigenPeptide LibrarymedicineAnimalsAmino Acid SequencePeptide libraryFungal vaccineMolecular Mimicrylcsh:RImmunityBiology and Life Sciencestossina killer mAb K20 Anti-idiotypic peptide mimic candidacidal activityMycotoxinsMolecular biologyRatsHemocyaninsHumoral Immunitybiology.proteinClinical Immunologylcsh:QFungal VaccinesPeptidesKeyhole limpet hemocyaninPLoS ONE
researchProduct

Safety and tolerability of omalizumab

2009

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic in…

medicine.medical_specialtyImmunologyOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal HumanizedInfectionsImmunoglobulin EAnti-asthmatic AgentNeoplasmsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsAnaphylaxisAsthmaClinical Trials as Topicbiologybusiness.industryIncidence (epidemiology)Antibodies Monoclonalmedicine.diseaseThrombocytopeniaAsthmaAntibodies Anti-IdiotypicClinical trialTolerabilityImmunologybiology.proteinbusinessAnaphylaxismedicine.drugClinical & Experimental Allergy
researchProduct